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Abstract
Background: To date, 102 genes have been reported as responsible for non-syndromic hearing loss, some of
which are associated with specific audiogram features. Four genes have been reported as causative for mid-
frequency sensorineural hearing loss (MFSNHL), among which TECTA is the most frequently reported; however,
the prevalence of TECTA mutations is unknown. To elucidate the prevalence of TECTA mutation in MFSNHL and
clarify genotype-phenotype correlations, we analyzed the genetic and clinical features of patients with MFSNHL.
Methods: Subjects with bilateral non-syndromic hearing loss were prescreened for GJB2 and m.1555A > G and m.
3243A > G mitochondrial DNA mutations, and patients with inner ear malformations were excluded. We selected
MFSNHL patients whose audiograms met the U-shaped criterion proposed by the GENDEAF study group, along
with those with shallow U-shaped audiograms, for TECTA analysis. All TECTA exons were analyzed by Sanger
sequencing. Novel missense variants were classified as possibly pathogenic, non-pathogenic, and variants of
uncertain significance, based on genetic data. To evaluate novel possibly pathogenic variants, we predicted
changes in protein structure by molecular modeling.
Results: Pathogenic and possibly pathogenic variants of TECTA were found in 4 (6.0%) of 67 patients with MFSNHL.
In patients with U-shaped audiograms, none (0%) of 21 had pathogenic or possibly pathogenic variants. In patients
with shallow U-shaped audiograms, four (8.7%) of 46 had pathogenic or possibly pathogenic variants. Two novel
possibly pathogenic variants were identified and two previously reported mutations were considered as variant of
unknown significance. The clinical features of patients with pathogenic and possibly pathogenic variants were
consistent with those in previous studies. Pathogenic or possibly pathogenic variants were identified in 3 of 23
families (13.0%) which have the family histories compatible with autosomal dominant and 1 of 44 families (2.3%)
which have the family histories compatible with sporadic or autosomal recessive.
Conclusions: TECTA mutations were identified in 6.0% of MFSNHL. These mutations were more frequent in patients
with shallow U-shaped audiograms than those with U-shaped audiograms, and in families which have the family
histories compatible with autosomal dominant than those with the family histories compatible with sporadic or
autosomal recessive.
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Background
Sensorineural hearing loss (SNHL) is one of the most
common sensory disorders in humans and its onset can
be influenced by numerous environmental and genetic
factors. Approximately 1 in 1000 newborns has congenital
bilateral SNHL and around half of these have underlying
genetic causes [1]. To date,102 genes have been reported
as responsible for non-syndromic hearing loss [2], some of
which are associated with specific audiogram features.
There are four genes reported to cause mid-frequency
hearing loss: EYA4 (DFNA10), TECTA (DFNA8/12,
DFNB21), COL11A2 (DFNA13), and CCDC50 (DFNA44)
[3]. Among these four genes, mutations in TECTA are
most frequently reported [4–7], and autosomal dominant
(AD) TECTA mutations (DFNA8/12) account for 2.9–4%
of all autosomal dominant non-syndromic sensorineural
hearing loss (ADNSHL) [4, 7].
The TECTA gene is located on chromosome 11q22–
q24, contains 23 exons, encodes 2155 amino acids, and
generates the protein, α-tectorin, a non-collagenous com-
ponent of the tectorial membrane [8]. The α-tectorin pro-
tein is composed of three distinct modules (Fig. 1) [9]: an
entactin-G1-like domain (ENT); a zonadhesin-like (ZA)
domain, comprising one von Willebrand factor type C
repeat, four von Willebrand factor type D repeats, and
three trypsin inhibitor-like repeats; and a zona pellucida
(ZP) domain. Both AD and autosomal recessive (AR)
inheritance patterns have been reported for mutations
in TECTA (DFNA8/12, OMIM # 601543; DFNB21,
OMIM # 603629 [8, 10]). Mouse models of deafness due
to TECTA mutations exhibit deformation of the tectorial
membrane [11–13]; however, the detailed mechanism by
which these mutations cause mid-frequency hearing loss
remains unknown.
Genotype-phenotype correlations for TECTA muta-
tions are shown in Fig. 1. In DFNB21, pathogenic vari-
ants result in premature protein truncation, all showing
prelingual, moderate to severe hearing loss, and flat or
U-shaped audiograms, regardless of the region of muta-
tion [10, 14, 15]. In DFNA8/12, pathogenic variants are
generally missense, with the audiogram dependent on the
region of the variant: high-frequency SNHL (HFSNHL)
associated with mutations of the ZA domain; and mid-
frequency SNHL (MFSNHL) associated with ZP domain
alterations [16, 17]. Recently, association with MFSNHL
were reported not only in the ZP domain mutations but
also in the ENT domain and N-terminal region of the ZA
domain [4].
Although MFSNHL is common among patients with
TECTA mutations, the prevalence of TECTA mutations
in this group is unknown. To elucidate the prevalence
of TECTA mutation in MFSNHL and clarify genotype-
phenotype correlations, we analyzed the genetic and
clinical features of patients presenting with MFSNHL.
Methods
Subjects
Subjects with MFSNHL were selected from patients who
had undergone genetic tests at our institute from 2002 to
2016 and tested for TECTA mutations. This study was ap-
proved by the Institutional Review Boards of our hospital
and each of the participating facilities, and conducted in
accordance with the Declaration of Helsinki. All subjects
or their parents (if the subject was less than 20 years old)
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Fig. 1 Domains of the TECTA and genotype-phenotype correlation of mutations. Pathogenic and possibly pathogenic variants found in this study
are shown at the top of the scheme and the novel variants are highlighted in bold. Under the scheme of the domains, reported genotype-phenotype
correlations for DFNA8/12 and DFNB21 are shown by bold lines with arrows for established phenotypes and a dotted line with arrows for proposed
phenotypes. The triangles indicate the positions of the VUS found in this study. ENT, entactin-G1-like domain; ZA, zonadhesin-like domain; C, von
Willebrand factor C domain; vWFD, von Willebrand factor D domain; T, trypsin inhibitor-like domain; ZP, zona pellucida domain; SNHL, sensorineural
hearing loss
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provided written informed consent for participation in this
project.
The criteria proposed by the GENDEAF study group
published in Hereditary Hearing Loss Homepage [2]
were used to categorize hearing-loss levels as follows:
mild, 20–40 dB HL; moderate, 41–70 dB HL; severe,
71–95 dB HL; profound, >95 dB HL (better hearing ear,
averaged over 0.5, 1, 2, and 4 kHz). The following criteria
were used to define hearing loss progression: progressive,
deterioration of >15 dB HL on average over the frequen-
cies 0.5, 1, and 2 kHz within a 10-year period [2]. We
judged the progression only in cases we could follow up
the audiograms for more than 10 years.
The process for selecting patients for TECTA gene
mutation testing is illustrated in Fig. 2. First, patients with
hearing loss due to GJB2, or mitochondrial m.1555A > G
or m.3243A > G, mutations were excluded based on
previous test results. Next, patients with bilateral non-
syndromic SNHL were selected, followed by exclusion of
patients with inner ear malformations by CT or MRI, if
performed. CT or MRI was performed in 1153 patients
among 1410 bilateral non-syndromic SNHL patients.
Next, patients were selected based on the mid-frequency
U-shaped criterion proposed by the GENDEAF study
group [2]: >15 dB HL difference between the poorest
threshold at mid-frequencies (1, 2 kHz) and those at
higher (4, 8 kHz) and lower (0.125, 0.25, 0.5 kHz) frequen-
cies. Since many patients with shallow U-shaped audio-
grams did not meet this requirement, an additional new
criterion was developed to include such patients: the poor-
est thresholds were identified at 0.5, 1, or 2 kHz, and the
criterion was that the threshold at 0.5 kHz was worse than
those at 0.125 and 0.25 kHz, and the threshold at 2 kHz
was worse than those at 4 and 8 kHz; patients who did
not meet the U-shaped criterion, but met this criterion for
a shallow U-shaped audiogram, were also selected for
TECTA analysis.
Genetic analysis
Genomic DNA samples were extracted from the periph-
eral blood of patients using a DNA extraction kit Geno-
mix (Biologica, Japan). The methods of screening for GJB2
and the mitochondrial m.1555A > G and m.3243A > G
mutations were shown in Additional file 1. For TECTA
analysis, the primers described in Additional file 2 were
used to amplify all exons of TECTA by PCR [17]. The
PCR conditions were as follows: 5 min denaturation at
Fig. 2 Flowchart of patient selection for TECTA analysis and the results. The selection of patients started with 1896 patients and patients with
GJB2 and mitochondrial mutations, and unilateral, conductive, and syndromic hearing loss, and inner ear anomaly were excluded. Then, the 1215
patients were subjected to U-shaped audiogram selection and 21 patients had U-shaped audiogram. Next, the 1194 patients who did not meet
the criterion for U-shaped audiogram were subjected to Shallow U-shaped audiogram selection and 46 patients had shallow U-shaped audiogram.
For the 67 patients (21 patients with U-shaped and 46 patients with shallow U-shaped) were tested for TECTA mutation. Finally, 4 patients (none with
U-shaped and 4 patients with shallow U-shaped) had pathogenic or possibly pathogenic variants
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95 °C; 35 cycles of 95 °C for 1 min, 58 °C for 1 min, and
72 °C for 2 min; followed by 72 °C for 2 min, and end-
ing with a holding period at 4 °C. PCR products were
purified and subjected to Sanger sequencing. Analysis was
performed using SeqScape ver3.0 Software (Applied Bio-
systems), by comparison with the NCBI human reference
sequence (GRCh37.p13). Frameshift, splice site (splice site
within ±2 nucleotides), and nonsense mutations were
judged pathogenic. For changes in splice sites within
10 bp of exon-intron boundaries, NNSPLICE (0.9 version)
[18] was used to predict the effect on splicing.
The reported TECTA missense variants were judged as
pathogenic when the variants co-segregate with the
phenotypes in family members, and judged as variants of
uncertain significance (VUS) when the variants did not
co-segregate with the phenotypes. Novel missense variants
were judged as possibly pathogenic if they met all of the
following criteria: 1) non-synonymous; 2) minor allele
frequency < 1% in all public databases, including 1000
GENOMES [19], NHLBI Exome Sequencing Project
(ESP6500) [20], Exome Aggregation Consortium (ExAC)
[21], Human Genetic Variation Database (HGVD) [22],
and integrative Japanese Genome Variation Database
(iJGVD) [23]; 3) high amino acid conservation (>90% in
primates and mammals, >50% in vertebrates) among up
to 12 primate, 50 mammal, and 38 vertebrate species
(Additional file 3) using the UCSC conservation tool [24];
4) consistency with phenotypes confirmed by hearing tests
in family members. Variants that did not satisfy criteria
1)–3) were judged as non-pathogenic. As patients with
TECTA mutations often show mild to moderate hearing
loss from childhood, individuals may not be aware of their
hearing loss; therefore, variants that met criteria 1)–3),
but failed criterion 4), were considered VUS. Furthermore,
the effect of missense mutation on the function of the
TECTA protein was predicted by computer analysis using
PolyPhen-2 [25] and Protein Variation Effect Analyzer
(PROVEAN v1.1.5) [26].
Molecular modeling
To evaluate novel possibly pathogenic variants (p.Y1900C
and p.S2017P), changes in the TECTA protein structure
were predicted by molecular modeling. The tyrosine at
residue 1900 of the TECTA protein is located in the N-
terminal part of the ZP domain (ZP-N), while the serine
at residue 2017 is located in the C-terminus of the ZP do-
main (ZP-C). As the structure of the TECTA ZP domain
is unknown, the human ZP domain structure was pre-
dicted using the crystal structure of chicken ZP3 (PDB ID:
3NK3, chain A), which has a high amino acid homology
to human ZP domains, as a template, using SWISS-
MODEL [27–29]. The TECTA protein can form dimers
through binding sites in the ZP-N domain, and the amino
acid sequence of this domain is important for dimer for-
mation [30, 31]. Therefore, as the p.Y1900C mutation may
affect ZP-N dimerization, additional analysis of the ef-
fect of this variant on dimerization was performed.
Since the dimeric structure of the ZP3 protein is un-
known, a predicted structure of the human TECTA
dimer was generated, using the predicted human ZP
domain structure and the dimeric human uromodulin
protein structure (PDB ID: 4WRN, chain A, chain B),
which has high homology with the human ZP domain,
as a template, using the display software, UCSF
Chimera 1.11 [30, 32], and the influence of p.Y1900C
mutation in this context was predicted.
Results
TECTA variants in patients with MFSNHL
As shown in the patient selection and exclusion diagram
(Fig. 2), 1215 patients received audiogram selection from
1896 probands. There were 21 patients with U-shaped au-
diograms meeting the GENDEAF criterion in one or both
ears (1.7% of patients who received U-shaped audiogram
selection) and 46 with shallow U-shaped audiograms
(3.9% of patients who were excluded by U-shaped audio-
gram selection). Family histories of these 67 patients with
U-shaped or shallow U-shaped audiograms were compat-
ible with AD in 23 patients (34.3%), AR in 10 patients
(14.9%), and sporadic in 34 patients (50.7%). Gene analysis
identified pathogenic and possibly pathogenic variants in
4 patients (6.0%) of the 67 patients. In patients with U-
shaped audiograms, none had pathogenic or possibly
pathogenic variants, one patient (4.8%) had VUS, and 20
patients (95.2%) had non-pathogenic variants or no vari-
ants (Additional file 4). In patients with shallow U-shaped
audiograms, two patients (4.3%) had pathogenic variants,
the other two patients (4.3%) had possibly pathogenic var-
iants, five patients (10.9%) had VUS, and 37 patients
(80.4%) had non-pathogenic variants or no variants.
Pathogenic or possibly pathogenic variants were identified
in 3 of 23 families (13.0%) which have the family histories
compatible with AD and 1 of 44 families (2.3%) which
have the family histories compatible with sporadic or AR.
A list of pathogenic variants, possibly pathogenic var-
iants, and VUS found in this study is presented in
Table 1, and a list of non-pathogenic variants is pro-
vided in Additional file 5. The DNA chromatograms of
pathogenic variants, possibly pathogenic variants, and
VUS are provided in Additional file 6. Three pathogenic
variants (p.R1890C, p.C633*, and c.65-3C > T) have
previously been reported. Two novel variants, p.Y1900C
and p.S2017P, identified in this study met criteria 1)–4)
(See Methods), and were predicted to have high pathogen-
icity by PolyPhen-2 and PROVEAN. Thus, they were con-
sidered possibly pathogenic variants.
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Molecular modeling of novel possibly pathogenic variants
in TECTA
Modeling structure of p.Y1900C in TECTA is shown in
Fig. 3. The tyrosine at residue 1900 (Y1900) is located in
the ZP-N domain, which is involved in dimer formation
via hydrogen bonds (arrows in Fig. 3a). Y1900 is predicted
to form a hydrogen bond with the lysine at residue 1807
(K1807) (arrowheads in Fig. 3a), to maintain the structure
of the dimerization site (Fig. 3a, b). However, in the model
of the protein containing the p.Y1900C mutation, this
hydrogen bond was absent (Fig. 3c). Hence, the p.Y1900C
mutation is likely to disrupt dimerization of the TECTA
protein via the ZP-N domain, and result in structural ab-
normality of the tectorial membrane.
The effect of the p.S2017P mutation, located in the
ZP-C domain, was not determined, as no significant alter-
ation in protein structure was predicted after introduction
of this mutation in the model; moreover, it is unknown
whether this region of the protein is involved in interac-
tions with other molecules.
Inheritance patterns, clinical features, and audiograms
associated with pathogenic or possibly pathogenic
variants and VUS in TECTA
Figure 4 shows the pedigrees of four families in which
pathogenic or possibly pathogenic variants were identi-
fied. Genotyping of the proband and family members, as
well as phenotypic characteristics, indicated an AD in-
heritance pattern in Family 1, Family 3, and Family 4
and an AR inheritance pattern in Family 2. In Family 3
and Family 4, novel possibly pathogenic variants with an
AD inheritance pattern were identified. In Family 4, the
mother of the proband (I-2) had the possibly pathogenic
variant and mild hearing loss, with a flat audiogram, in
contrast to the moderate hearing loss and U-shaped
audiogram of the proband (II-1). Given this discrepancy,
the potential pathogenicity of this variant should be con-
sidered with caution.
Clinical data of the four families with pathogenic or
possibly pathogenic variants are presented in Table 2.
The onset of hearing loss was in the first decade of life
in all families. The level of hearing loss was mild to
moderate in all cases. All of the probands had shallow
U-shaped audiograms. No progression was observed in
any case during the follow-up period according to the
criteria used in the present study. In Family 1, the most
recent audiogram of the father of the proband, who had
the mutation, was flat, and the hearing of the proband
deteriorated at both high and low frequencies with age,
resulting in an audiogram similar to that of the father
(Fig. 4). The word recognition score (WRS) was 70–90%
in all cases (Additional file 7).
Figure 5 and Table 3 shows the pedigrees, audio-
grams, and clinical data of Family 5–10 in which VUS
were identified. In Family 7, Family 8 and Family 10,
the reported TECTA mutations did not show typical
family history of AD or did not segregate in family mem-
bers who were not tested for hearing loss, and/or TECTA
mutations. It is possible that this may be explained by
mild phenotype, de novo mutation, or phenocopy. In
Family 7, the parents of the proband (II-3 and II-4) were
not known to have hearing loss. Therefore, the mutation
may be de novo in the proband. Alternatively, the father
(II-3) may carry the mutation and have mild hearing loss
that had not been noted. In Family 8, the father (II-1) car-
ried the mutation but did not present with hearing loss. In
addition, the allele frequency of this variant in Japanese is
high (0.008) for the cause of DFNA8/12. Although the
possibility of the low penetrance of this variant cannot be
denied, these data suggest that this variant is unlikely to
be pathogenic. In Family 10, the mother of the proband
(II-2) presented with hearing loss, but did not have the
mutation. As the peak frequency of the U-shaped audio-
gram and the onset of the hearing loss were quite different
in the mother from those in the proband (III-2), the cause
of hearing loss may be different in the two individuals
(suggesting phenocopy), and the mutation in the proband
Fig. 3 Modeling of possibly pathogenic variants in TECTA. a ZP-N dimer structure of TECTA. White and light green colors represent monomers.
Light blue lines, hydrogen bonds; yellow, the side chain of Y1900; purple, K1807; arrowheads, hydrogen bonds between Y1900 and K1807; arrows,
hydrogen bonds connecting ZP-N domains. b Monomer structure of wild type ZP-N. c Monomer structure of ZP-N with p.Y1900C mutation. The
side chain of C1900 is indicated in orange
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could be de novo or inherited from the father (II-1),
who may have the mutation and mild hearing loss that
had not been noted. In Family 5, Family 6, and Family
9, novel VUS were identified. In these families, similar
to Family 7 and Family 10, individuals reporting normal
hearing who had not had hearing tests (Family 5, II-4;
Family 6, I-1 and I-2; Family 9, II-1) may have had mild
hearing loss. In Family 5, the lack of TECTA mutation
in the father (of proband, II-1) with hearing loss, sug-
gests that his hearing loss may be due to other causes,
such as presbycusis. In Family 6, the mutation in the
proband could be de novo.
Family 2
Family 3 Family 4
Family 1
Fig. 4 Pedigrees and audiograms of patients with pathogenic and possibly pathogenic TECTA variants. P represents the proband. Horizontal bars
above circles and squares indicate subjects who underwent genetic testing. Novel variants are presented in bold
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Discussion
The prevalence of TECTA mutations (DFNA8/12) has
been investigated in only ADNSHL population, and it was
reported as 2.9–4.0% [4, 7]. The present study revealed
the prevalence of TECTA mutation in patients with
MFSNHL for the first time. Pathogenic and possibly
pathogenic variants of TECTA were found in 4 (6.0%) of
67 patients with bilateral non-syndromic MFSNHL who
were prescreened for GJB2 and m.1555A > G and
m.3243A > G mitochondrial DNA mutations. In addition,
six patients (9.0%) had VUS, which may underlie their
MFSNHL. Among patients with U-shaped audiograms,
Table 2 Clinical data of patients with pathogenic or possibly pathogenic variants
Family Genotypes Case Age of
diagnosis
Age at the latest
Examination
Audiometric
configuration
Hearing loss
Severitya
Progressionb Vestibular
symptoms
Inheritance
patternc
1 p.[R1890C];[=] II-1 9 y 52 y Flat Moderate Unknown Absent AD
III-2 7 y 23 y Shallow U-shaped Moderate Stable Absent
2 c.[65-3C > T];p.[C633*] II-1 4 y 17 y Shallow U-shaped Moderate Stable Absent AR
3 p.[Y1900C];[=] II-2 9 y 37 y U-shaped Moderate Unknown Absent AD
III-1 2 y 15 y Shallow U-shaped Moderate Stable Absent
4 p.[S2017P];[=] I-2 Unknown 43 y Flat Mild Unknown Absent AD
II-1 8 m 3 y Shallow U-shaped Moderate Unknown Absent
AD autosomal dominant; AR autosomal recessive
aMild, 20–40 dB HL; moderate, 41–70 dB HL; severe, 71–95 dB HL; profound, >95 dB HL (better hearing ear, averaged over 0.5, 1, 2, and 4 kHz)
bProgressive, deterioration of >15 dB HL in the average over the frequencies of 0.5, 1, and 2 kHz within a 10-year period
cInheritance pattern estimated from genotypes and phenotypes of family members
Family 5 Family 6 Family 7
onset: 33 y onset: 0 y
Family 9 Family 10Family 8
Fig. 5 Pedigrees and audiograms of patients with VUS. P represents the proband. Horizontal bars above circles and squares indicate subjects who
underwent genetic testing. Novel variants are presented in bold
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none had a pathogenic variant and one (2.2%) had VUS.
In contrast, four patients (8.7%) with shallow U-shaped
audiograms had pathogenic or possibly pathogenic vari-
ants and five (10.9%) had VUS. Thus, TECTA mutations
are likely to be more prevalent among patients with
shallow U-shaped audiograms than those with U-shaped
audiograms. The frequency of TECTA mutations was
higher (13.0%) among families which have the family
histories compatible with AD than among those which
have the family histories compatible with sporadic or
AR (2.3%). These conclusions may be limited to the
Japanese population because all of the subjects of this
study were Japanese. Another limitation of this study is
that we have not investigated causes other than TECTA
and we cannot deny the possibility that other causes
might have effected on hearing of the present patients.
However, the significance of the TECTA variants would
not be likely to be reversed solely by such effects, since
we evaluated these variants with the strictly established
criteria.
Regarding genotype-phenotype correlation, three patho-
genic and possibly pathogenic AD variants (p.R1890C,
p.Y1900C, p.S2017P) were located in the ZP domain (Fig.
1). This correlation between ZP domain mutations and
MFSNHL is consistent with previous studies [16, 17]. In
one AR family, identified pathogenic variants (p.C633*,
and c.65-3C > T) were truncating mutations and the mod-
erate U-shaped hearing loss was present. This correlation
between AR truncating mutations in any regions and
MFSNHL is also consistent with previous studies [10, 14,
15]. Five VUS of AD inheritance patterns were located in
the ZA domain or between ZA and ZP domain, two of
which have been reported previously [4, 6], indicating that
regions other than the ZP domain may also be associated
with MFSNHL. Since novel TECTA mutations keep in-
creasing [33, 34], genotype-phenotype correlations may be
expanded along with the progress of genetic studies. Be-
cause two previously reported mutations, p.L1439I and
p.P1791R, were regarded as VUS in the present study,
pathogenicity of each variants needs to be validated with
caution.
Regarding the clinical features of hearing loss related
to TECTA mutations, all patients with mutations had
good WRSs and all the patients whose audiograms
could be evaluated for more than 10 years showed non-
progressive hearing loss. It was previously reported that
WRSs in patients with TECTA mutations are superior
to those in individuals with age-related hearing impair-
ment presenting with the same levels of hearing loss
[17]. This phenomenon was explained by the fact that
thresholds are maintained at high frequencies [17], and
the lack of primary damage to the function of hair cells
and cochlear nerves in TECTA patients may also be
relevant. Patients with cysteine-replacing mutations in
TECTA exhibit progressive hearing loss, while those
with other mutations have non-progressive symptoms
[16, 17]. None of the mutations in the present study
were cysteine-replacing, and none of the patients had
progressive hearing loss; therefore, our data are in
agreement with the findings of previous studies.
The present study revealed that more than 90% of non-
syndromic MFSNHL is likely caused by factors other than
TECTA mutations. Thus, there may be few unknown
causative genes for MFSNHL with high prevalence, or
many other causative genes with low prevalence. Other
than TECTA, three genes, COL11A2 (DFNA13, DFNB53)
[35, 36], EYA4 (DFNA10) [37], and CCDC50 (DFNA44)
[38], are reported to cause MFSNHL. The frequency of
mutations in these genes and other unknown causative
genes could be determined by comprehensive genetic test-
ing using next generation sequencing in patients with
MFSNHL in future investigations.
Table 3 Clinical data of patients with VUS
Family Genotypes Case Age of
diagnosis
Age at the latest
Examination
Audiometric
configuration
Hearing loss
Severitya
Progressionb Vestibular
symptoms
Inheritance
patternc
5 p.[L940I];[=] II-1 40 y 81 y High-Frequency Moderate Unknown Absent AD
III-1 40 y 47 y Shallow U-shaped Moderate Unknown Absent
III-2 33 y 44 y High-Frequency Mild Unknown Present
6 p.[R1033Q];[=] II-1 46 y 57 y Shallow U-shaped Moderate Unknown Absent AD
7 p.[L1439I];[=] III-1 6 y 16 y Shallow U-shaped Moderate Stable Absent AD
8 p.[L1439I];[=] III-1 16 y 38 y U-shaped Mild Stable Absent AD
9 p.[V1646 M];[=] III-1 8 y 23 y Unknown Moderate Unknown Unknown AD
III-3 3 y 21 y Shallow U-shaped Moderate Stable Absent
10 p.[P1791R];[=] III-2 6y 13 y Shallow U-shaped Mild Unknown Absent AD
AD autosomal dominant; AR autosomal recessive
aMild, 20–40 dB HL; moderate, 41–70 dB HL; severe, 71–95 dB HL; profound, >95 dB HL (better hearing ear, averaged over 0.5, 1, 2, and 4 kHz)
bProgressive, deterioration of >15 dB HL in the average over the frequencies of 0.5, 1, and 2 kHz within a 10-year period
cInheritance pattern estimated from genotypes and phenotypes of family members
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Conclusions
TECTA gene mutations were identified in 6.0% of
MFSNHL and were more frequent in cases with shallow
U-shaped audiograms than those with U-shaped audio-
grams. Two novel possibly pathogenic variants were
identified and two previously reported mutations were
considered as VUS. The frequency of TECTA mutations
was higher in families with the family history compatible
with AD than in those which have the family history
compatible with sporadic or AR.
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